April 28 (Reuters) - Revvity ( RVTY ) reported

first-quarter results above Wall Street estimates and maintained

its full-year profit forecast on Monday, helped by steady demand

from biotech clients for medical equipment used for drug

research.

The medical equipment maker, which generates over half its

sales outside the United States, said revenues will benefit due

to a weaker dollar and slightly raised its full-year sales

outlook.

While maintaining its annual profit forecast of $4.90 to $5

per share on an adjusted basis, the company now anticipates 2025

revenue to be between $2.83 billion and $2.87 billion, compared

to the previous projection of $2.80 billion to $2.85 billion.

Revvity's ( RVTY ) "clean beat" leaves "very little to quibble with"

in this macroenvironment, said Bernstein analyst Eve Burstein.

Investors have said the biotech sector's funding crunch,

which was expected to improve this year, could be prolonged due

to policy uncertainty from the Trump administration.

Shares of Revvity ( RVTY ) have fallen 15.5% so far this year.

"Our first-quarter performance positions us well for the

remainder of the year as we continue to adapt to an evolving

macroeconomic backdrop," said CEO Prahlad Singh.

Larger peers Thermo Fisher Scientific ( TMO ) and Danaher ( DHR )

, who also posted strong quarterly results last week, had

warned of a potential hit to results due to a looming threat of

tariffs and other uncertainty.

The Massachusetts-based Revvity ( RVTY ) earned a quarterly adjusted

profit of $1.01 per share, above analysts' estimates of 95 cents

per share, according to data compiled by LSEG. It reported

first-quarter revenue of $664.8 million, slightly above

estimates of $661.2 million.

The company's life sciences unit, which provides reagents

and instruments for drug discovery and development, brought in

revenue of $340.4 million, compared with estimates of $332

million.